Medtronic Bets On Blockbuster Hypertension Market With Ardian Acquisition
This article was originally published in The Gray Sheet
Medtronic's $800-million-plus bet on still-early-stage catheter technology for treating hypertension is a risk worth taking, company watchers suggest, considering many of the device giant's core offerings are in mature markets with paltry growth prospects.
You may also be interested in...
FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.
A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint
Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.